Showing results (81-90 of 100) with videos related to
Sort By:
Pageof 10
Frontiers in Immunology|May 20, 2021
Immunological Biomarkers of Fatal COVID-19: A Study of 868 PatientsEsperanza Martín-Sánchez, Juan José Garcés, Catarina Maia, et al.Hematological Oncology|May 31, 2022
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trialsEnrica Antonia Martino, Concetta Conticello, Elena Zamagni, et al.Blood Advances|September 29, 2021
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunologyCirino Botta, Catarina Maia, Juan-José Garcés, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple MyelomaCamila Guerrero, Noemi Puig, Maria-Teresa Cedena, et al.European Journal of Haematology|January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' RecommendationsAlessandro Corso, Monia Marchetti, Monica Galli, et al.Leukemia|October 10, 2019
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease disseminationJuan-Jose Garcés, Michal Simicek, Marco Vicari, et al.Journal for Immunotherapy of Cancer|February 18, 2021
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemiaDaniele Caracciolo, Caterina Riillo, Andrea Ballerini, et al.Annals of Hematology|September 9, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapiesDanilo De Novellis, Salvatore Palmieri, Stefano Rocco, et al.Blood|April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myelomaCatarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.Pageof 10